← Back to Search

Biomarker Validation Tests for Mesothelioma

N/A
Recruiting
Led By Raphael Bueno, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be 18 years of age or older.
All adult patients with a diagnosis of malignant pleural mesothelioma undergoing diagnostic pleural biopsy
Must not have
Any patient who is found to be unsuitable for surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new way to figure out how advanced someone's mesothelioma is and what their outlook is.

Who is the study for?
This trial is for adults diagnosed with malignant pleural mesothelioma who are undergoing various procedures like VATS resections, diagnostic pleural biopsy, or pleuroscopy. It's not suitable for patients deemed unfit for surgery, treatment, or diagnosis.
What is being tested?
The study is evaluating new tests called MPT Test and CLDN15/VIM Test to better determine the stage and prognosis of malignant pleural mesothelioma in individuals undergoing specific medical procedures.
What are the potential side effects?
Since this trial involves diagnostic tests rather than treatments, there may be minimal side effects related to the procedure itself such as discomfort at the biopsy site or a low risk of infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am an adult diagnosed with mesothelioma and will have a biopsy.
Select...
I have been diagnosed with mesothelioma and am undergoing a specific type of surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been deemed unsuitable for surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pre-treatment Prognostic Algorithm Validation
Secondary study objectives
Evaluation of Molecular Tests Base on RNA Expression

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRiSExperimental Treatment2 Interventions
* The specimens to be collected will include at least five pleural biopsy samples * MPT test and the CLDN15/VIM test will be performed

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,111,877 Total Patients Enrolled
94 Trials studying Mesothelioma
8,391 Patients Enrolled for Mesothelioma
Dana-Farber Cancer InstituteLead Sponsor
1,113 Previous Clinical Trials
358,641 Total Patients Enrolled
9 Trials studying Mesothelioma
781 Patients Enrolled for Mesothelioma
Raphael Bueno, MDPrincipal Investigator - Brigham and Women's Hospital
Brigham & Women's Faulkner Hospital, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Milford Regional Medical Center
Harvard Medical Sch (Medical School)
Boston Medical Center (Residency)
4 Previous Clinical Trials
1,401 Total Patients Enrolled
2 Trials studying Mesothelioma
141 Patients Enrolled for Mesothelioma

Media Library

MPT Test Clinical Trial Eligibility Overview. Trial Name: NCT03683680 — N/A
Mesothelioma Research Study Groups: MRiS
Mesothelioma Clinical Trial 2023: MPT Test Highlights & Side Effects. Trial Name: NCT03683680 — N/A
MPT Test 2023 Treatment Timeline for Medical Study. Trial Name: NCT03683680 — N/A
~34 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top